DBV Technologies SA
DBVTHealthcare|Biotechnology|France
$16.49
+0.41 (+2.55%)
Tangible Book
$3.53
Earnings Power
$2.43
Clinical Trials (18)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT05741476 Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Children 4-7 Years of Age | Allergy, Peanut | P3 | Active | 600 | RCT, Double-blind | DBV712, DBV712 |
| NCT07003919 Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers) | Allergy, Peanut Allergy | P3 | Recruiting | 480 | RCT, Double-blind | — |
| NCT03859700 Follow-up of the EPITOPE Study to Evaluate Long-term Efficacy and Safety of DBV712 in Young Children | Peanut Allergy | P3 | Completed | 304 | Open-label | DBV712 250 mcg |
| NCT03013517 Follow-up of the PEPITES Study to Evaluate Long-term Efficacy and Safety of Viaskin Peanut in Children | Peanut Allergy | P3 | Unknown | 300 | Open-label | Viaskin Peanut 250µg |
| NCT02636699 Efficacy and Safety of Viaskin Peanut in Children With Immunoglobulin E (IgE)-Mediated Peanut Allergy | Peanut Allergy | P3 | Completed | 500 | RCT, Double-blind | Viaskin Peanut 250mcg, Placebo |
| NCT03211247 Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Young Children 1-3 Years of Age | Peanut Allergy | P3 | Completed | 414 | RCT, Double-blind | Part A Viaskin Peanut 250 mcg, Part A Viaskin Peanut 100 mcg, Part A Placebo, Part B Viaskin Peanut 250 mcg, Part B Placebo |
| NCT02916446 Safety Study of Viaskin Peanut to Treat Peanut Allergy | Peanut Allergy | P3 | Completed | 393 | RCT, Double-blind | Viaskin Peanut 250 mcg, Placebo |
| NCT01197053 Epicutaneous Immunotherapy in Peanut Allergy in Children | Peanut Allergy | P2 | Completed | 60 | RCT, Double-blind | Epicutaneous Immunotherapy, placebo of peanut |
| NCT02579876 Milk Patch for Eosinophilic Esophagitis | Eosinophilic Esophagitis, Milk Allergy | P2 | Completed | 20 | RCT, Double-blind | Viaskin Milk 500 mcg, Viaskin Placebo |
| NCT02223182 Efficacy and Safety of Viaskin Milk in Children With IgE-Mediated Cow's Milk Allergy | Food Allergy | P1P2 | Completed | 198 | RCT, Double-blind | Viaskin Milk 150 mcg, Viaskin Milk 300 mcg, Viaskin Milk 500 mcg, Viaskin Placebo |
| NCT01955109 Follow-up of the VIPES Study to Evaluate Efficacy and Safety of Viaskin Peanut in Adults and Children | Peanut Allergy | P2 | Completed | 171 | Open-label | Viaskin Peanut 250 mcg |
| NCT01675882 Efficacy and Safety of Several Doses of Viaskin Peanut in Adults and Children With Peanut Allergy | Peanut Allergy | P2 | Completed | 221 | RCT, Double-blind | Viaskin Peanut 50 mcg, Viaskin Peanut 100 mcg, Viaskin Peanut 250 mcg, Viaskin Placebo |
| NCT04492683 Diagnostic Accuracy and Safety of DBV1605 for the Diagnosis of Non-IgE Mediated Cow's Milk Allergy in Children | Cow's Milk Allergy | P2 | Unknown | 230 | Double-blind | — |
| NCT01170286 Safety of Epicutaneous Immunotherapy for the Treatment of Peanut Allergy | Peanut Allergy | P1 | Completed | 100 | RCT, Double-blind | Whole peanut extract, Placebo formulation |
| NCT03352726 A Study to Assess the Biological Potency of Peanut Allergen Extract in Adolescent and Adult Peanut Allergic Subjects | Peanut Allergy | P1 | Completed | 27 | Open-label | DBV712 IHRP |
| NCT03035370 Viaskin Pertussis Vaccine Trial | Whooping Cough | P1 | Completed | 102 | RCT, Double-blind | Viaskin PT 25 mcg, Viaskin PT 50 mcg, Viaskin PT Placebo, Boostrix™ |
| NCT04371627 Viaskin® Peanut (DBV712) Expanded Access Protocol | Peanut Allergy | NO_LONGER_AVAILABLE | — | — | Viaskin Peanut | |
| NCT05424731 Expanded Access Protocol of Viaskin® Peanut (DBV712) in Peanut-allergic Children | Peanut Allergy | AVAILABLE | — | — | — |